- uBriGene Biosciences has rebranded its GMP lentiviral vector manufacturing platform as LVV Turbo™ and announced a partnership with Syenex to integrate UltraCell™ technology.
- The combined LVV Turbo™ + UltraCell™ platform is designed to improve productivity, downstream recovery, and transduction titers in lentiviral vector manufacturing.
uBriGene Biosciences has announced the rebranding of its GMP lentiviral vector manufacturing platform to LVV Turbo™, alongside a strategic partnership with Syenex to integrate the UltraCell™ technology into its workflow. The company operates as a global lentivirus CDMO focused on Advanced Therapy Medicinal Product GMP development and contract manufacturing.
The LVV Turbo™ + UltraCell™ platform brings together three technologies intended to address established challenges in lentiviral vector production. These include the LVV Turbo™ 293TH suspension cell line, which the company says can deliver up to five times higher transduction titers than traditional adherent 293T cells, and a fully closed downstream purification process designed to avoid sterile filtration and improve vector recovery.
According to uBriGene, traditional GMP lentivirus manufacturing can lose more than 70% of vector during sterile filtration. The closed downstream process used in LVV Turbo™ is intended to eliminate this step and enable up to 80% recovery while maintaining vector integrity. Through the partnership with Syenex, UltraCell™ technology is incorporated to improve transducing units per particle for T cells, with reported increases of up to five-fold across multiple genes of interest.
“Our LVV Turbo™ platform resolves the core bottlenecks in LVV manufacturing—boosting productivity, increasing yield, and lowering cost.”
Dr. Xiulian Sun, Chief Technology Officer at uBriGene Biosciences
uBriGene added that the LVV Turbo™ platform can enable up to 1,500 CAR-T doses from a 20-litre production run, addressing lentiviral vector supply constraints in both ex vivo and in vivo CAR-T programmes.
